ClinicalTrials.Veeva

Menu

First Evaluation of a Craniofacial Peripheral Nerve Stimulation System in Chronic Migraine (RELIEF)

S

Salvia BioElectronics

Status

Active, not recruiting

Conditions

Chronic Migraine

Treatments

Device: PRIMUS

Study type

Interventional

Funder types

Industry

Identifiers

NCT05858801
SCI-02-CM

Details and patient eligibility

About

The purpose of this study is to demonstrate the safe use of the PRIMUS system in subjects with chronic migraine. This is a single-center, open label, prospective, early feasibility study to collect initial clinical data on the PRIMUS system for the treatment of chronic migraine.

Enrollment

7 patients

Sex

All

Ages

18 to 84 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

  • Able and willing to provide informed consent
  • Age ≥ 18 years and ≤ 84 years at time of consent
  • Documented Chronic Migraine, defined as at least eight migraine days/month, for at least 1 year.
  • Developed migraine before the age of 50
  • Documented failure of 3 or more other preventive therapies (failure meaning ineffective, provoked unacceptable side-effects or contra-indicated) from which at least 1 of the following 2: CGRP mAbs or Onabotulinumtoxin A
  • Have at least 1 headache free day per month
  • Stable on preventive migraine drugs and alternative treatment for at least three months prior to enrollment.
  • Agree to refrain from starting new preventive migraine drugs or other preventive alternative migraine treatments, from 4 weeks before entering the baseline period throughout the duration of the study.
  • MRI available (not older than 4 years prior to study enrollment) or willing to undergo an MRI to exclude structural lesions potentially causing headache
  • Able and willing to complete a daily headache eDiary

Main Exclusion Criteria:

  • Any other chronic primary or secondary headache disorder, unless they can clearly differentiate them from migraine attacks, based on the quality of pain and associated symptoms.
  • Concomitant neuromodulation
  • Previous failure to an implantable neuromodulation device for neurovascular headache
  • Have an existing Active Implantable Medical Device nearby the implant location (e.g. DBS, cochlear implant, ...)
  • Metal implants in the skull (e.g. skull plates, seeds) nearby the implant.
  • Have a pacemaker of implantable cardioverter defibrillator (ICD)
  • Current Opioid Use, defined as one or more opioids on more than 4 days/month for 3 consecutive months.
  • Use of botulinum toxin injections in the past 3 months.
  • Women of childbearing age who are pregnant, nursing or not using contraception

Trial design

Primary purpose

Device Feasibility

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

7 participants in 1 patient group

PRIMUS
Experimental group
Description:
PRIMUS system
Treatment:
Device: PRIMUS

Trial contacts and locations

1

Loading...

Central trial contact

Wim Pollet, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems